Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Somasundaram, Chezian | Sundarapandiyan, Karuna | Keler, Tibor | Deo, Yashwant M. | Graziano, Robert F.; *
Affiliations: Medarex Inc., 1545 Route 22 East, P.O. Box 992, Annandale, NJ 08801, USA
Correspondence: [*] Correspondence: Dr. Robert F. Graziano, Medarex Inc., 1545 Route 22 East, P.O. Box 992, Annandale, NJ 08801, USA. Tel.: +908 713 6000 Ext. 306; Fax: +908 713 6013; E-mail: rgrazian@injersey
Abstract: A trispecific F(ab′)3 antibody conjugate (TAC) with specificities for the Fcγ receptor I (FcγRI/CD64), the epidermal growth factor receptor (EGFR) and the HER2/neu antigen has been developed to redirect effector cell-mediated cytotoxicity against cancer cells expressing both or either of the tumor-associated antigens. The TAC was constructed in two steps using the sulfhydryl-specific cross-linker o-phenylenedimaleimide (o-PDM). In step one, a bispecific antibody was prepared by linking the Fab′ fragments of mAb m22 (a murine IgG1 specific for FcγRI) and mAb H425 (a humanized IgG1 antibody recognizing EGFR). The conjugation efficiency was about 60%. the second step, the Fab′ fragment of mAb 520C9, a murine IgG1 specific for HER2/neu, was coupled to the bispecific antibody made in step one. About 40% antibody. The purity of the TAC was more than 90% purification. The TAC was characterized in vitro for its ability to bind specifically to all the three antigens and to kill target cells expressing the tumor antigens. In contrast to bispecific conjugates that can only target cells expressing either of the tumor antigens, the TAC was able to bind both the antigens more efficiently in cell-binding assays and to kill tumor cells expressing EGFR and HER2/neu antigens.
Keywords: Trispecific Antibody Conjugate, EGFR, HER2/neu, FcγRI, ADCC
DOI: 10.3233/HAB-1999-9105
Journal: Human Antibodies, vol. 9, no. 1, pp. 47-54, 1999
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl